Intelligence Platform

Patents

Browse 67 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12365719

CD80 extracellular domain polypeptides and their use in cancer treatment

Five Prime Therapeutics, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12319738

Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer

Five Prime Therapeutics, Inc. · Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12195535

Antibodies binding to VISTA at acidic pH

Five Prime Therapeutics, Inc. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173069

Antibodies binding to vista at acidic pH

Five Prime Therapeutics, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091462

Antibodies binding to vista at acidic pH

Five Prime Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11975046

Medical use of interferon-lambda for the treatment of fibrosis

Five Prime Therapeutics, Inc. · Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11939383

B7-H4 antibodies and methods and use thereof

Five Prime Therapeutics, Inc. · Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11814431

B7-H4 antibodies and methods of use thereof

Five Prime Therapeutics, Inc. · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603406

Antibodies binding to VISTA at acidic pH

Five Prime Therapeutics, Inc. · Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421034

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Five Prime Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401328

Antibodies binding to ILT4

Five Prime Therapeutics, Inc. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306150

Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

Five Prime Therapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11306144

B7-H4 antibodies and methods of use thereof

Five Prime Therapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11235059

Afucosylated anti-FGFR2IIIB antibodies

Five Prime Therapeutics, Inc. · Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186646

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Five Prime Therapeutics, Inc. · Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098103

CD80 extracellular domain polypeptides and their use in cancer treatment

Five Prime Therapeutics, Inc. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11091555

Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 che

Five Prime Therapeutics, Inc. · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10982001

Methods of treating conditions with antibodies that bind colony stimulating factor 1 recep

Five Prime Therapeutics, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975153

Methods of treating conditions with antibodies that bind colony stimulating factor 1 recep

Five Prime Therapeutics, Inc. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10822421

Methods of treating conditions with antibodies that bind colony stimulating factor 1 recep

Five Prime Therapeutics, Inc. · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10799559

NOPE for treatment of pathological muscle loss and weakness

Five Prime Therapeutics, Inc. · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10730949

Method of treating PVNS with anti-CSF1R antibodies

Five Prime Therapeutics, Inc. · Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted